Drake & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$724K Sell
2,735
-830
-23% -$219K 0.11% 55
2026
Q2
$905K Sell
3,565
-2,890
-45% -$674K 0.15% 43
2026
Q1
$1.58M Sell
6,455
-3,464
-35% -$807K 0.3% 31
2025
Q4
$2.05M Sell
9,919
-4,734
-32% -$936K 0.41% 26
2025
Q3
$2.73M Sell
14,653
-7,105
-33% -$1.22M 0.57% 29
2025
Q2
$3.32M Buy
21,758
+6,862
+46% +$1.05M 0.81% 20
2025
Q1
$2.47M Buy
14,896
+5,227
+54% +$818K 0.69% 19
2024
Q4
$1.48M Buy
9,669
+5,704
+144% +$884K 0.42% 28
2024
Q3
$642K Buy
3,965
+611
+18% +$97.3K 0.21% 35
2024
Q2
$490K Buy
3,354
+338
+11% +$50.3K 0.18% 39
2024
Q1
$477K Buy
3,016
+34
+1% +$5.41K 0.17% 45
2023
Q4
$467K Sell
2,982
-240
-7% -$36.8K 0.19% 42
2023
Q3
$502K Buy
3,222
+594
+23% +$98K 0.23% 33
2023
Q2
$435K Sell
2,628
-1,352
-34% -$218K 0.19% 39
2023
Q1
$617K Buy
3,980
+1,661
+72% +$268K 0.3% 27
2022
Q4
$410K Buy
+2,319
New +$400K 0.22% 35

Other funds holding JNJ

Drake & Associates's JNJ Position: Q3 2026 in Review

Drake & Associates reduced its Johnson & Johnson (JNJ) stake by 23% in Q3 2026, selling an estimated $219K and leaving 2,735 shares worth $724K. The position accounts for 0.11% of the portfolio, ranked #55.

Drake & Associates first reported a position in JNJ in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.32M in Q2 2025. 4,734 funds tracked by Wall St. Rank hold JNJ as of Q3 2026.

  • Drake & Associates held 2,735 shares of Johnson & Johnson worth $724K as of Q3 2026.
  • Drake & Associates sold 830 Johnson & Johnson shares in Q3 2026, an estimated $219K.
  • Johnson & Johnson made up 0.11% of Drake & Associates's portfolio in Q3 2026, its #55 holding.
  • Drake & Associates first reported a position in Johnson & Johnson in Q4 2022 and has held it in 16 quarters since.
  • Drake & Associates's Johnson & Johnson position peaked at $3.32M in Q2 2025.
  • 4,734 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2026.

Based on Drake & Associates's 13F filing for Q3 2026, filed 18 Nov 2026.